| Pay vs Performance Disclosure | 12 Months Ended |
| Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) |
| Pay vs Performance Disclosure | | | | |
| Pay vs Performance Disclosure, Table | Year Summary Compensation Table Total for PEO (1) Compensation Actually Paid to PEO (1)(2) Average Summary Compensation Table Total for Non-PEO NEOs (1) Average Compensation Actually Paid to Non-PEO NEOs (1)(2) Total Shareholder Return Peer Group Total Shareholder Return (3) Net (Loss) Income (millions) Adjusted EBITDA % (4) 2023 $ 7,059,325 $ (1,816,558) $ 1,675,659 $ (222,491) $ 81.17 $ 143.18 $ (100.2) 18.1 % 2022 $ 8,523,732 $ (4,535,253) $ 1,836,308 $ (42,128) $ 113.60 $ 140.29 $ 243.1 20.1 % 2021 $ 9,199,748 $ 28,844,127 $ 2,474,388 $ 4,661,522 $ 152.02 $ 143.09 $ 340.5 19.7 % 2020 $ 7,370,894 $ 14,441,335 $ 1,640,642 $ 2,321,660 $ 113.80 $ 113.45 $ 33.3 13.0 % | | | |
| Company Selected Measure Name | adjusted EBITDA | | | |
| Named Executive Officers, Footnote | The PEO for 2023, 2022, 2021 and 2020 was Amir Aghdaei. The non-PEO NEOs for 2022, 2021 and 2020 were Howard Yu (Senior Vice President and Chief Financial Officer), Jean-Claude Kyrillos (Senior Vice President of Diagnostics and Digital Solutions), Patrik Eriksson (Senior Vice President, President of Nobel Biocare), and Mark Nance (Senior Vice President, General Counsel and Secretary). The non-PEO NEOs for 2023 were Mr. Yu, Mr. Kyrillos, Mr. Eriksson, Mr. Nance, Stephen Keller (Principal Financial Officer) and Eric Conley (Senior Vice President and President, Orthodontics). | | | |
| Peer Group Issuers, Footnote | Total shareholder return (“TSR”) is determined based on the value of an initial fixed investment of $100 on December 31, 2019. The Peer Group TSR set forth in this table utilizes the S&P 500 Health Care Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2023. Historical stock performance is not necessarily indicative of future stock performance. | | | |
| PEO Total Compensation Amount | $ 7,059,325 | $ 8,523,732 | $ 9,199,748 | $ 7,370,894 |
| PEO Actually Paid Compensation Amount | $ (1,816,558) | (4,535,253) | 28,844,127 | 14,441,335 |
| Adjustment To PEO Compensation, Footnote | Equity award adjustments Year Executive(s) SCT Total Deduct grant date fair value of equity awards reported in SCT Add year-end value of unvested equity awards granted in year Change in value of unvested equity awards granted in prior years Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year Change in value of equity awards granted in prior years which vested in year 2023 PEO $ 7,059,325 $ (5,200,178) $ 1,613,810 $ (5,825,994) $ 536,479 Non-PEO NEOs $ 1,675,659 $ (971,147) $ 212,290 $ (332,625) $ (891,449) $ 84,781 2022 PEO $ 8,523,732 $ (5,100,321) $ 2,608,474 $ (11,166,139) $ 599,000 Non-PEO NEOs $ 1,836,308 $ (1,025,211) $ 537,397 $ (1,446,374) $ 55,752 2021 PEO $ 9,199,748 $ (4,700,022) $ 6,694,551 $ 14,514,792 $ 3,135,059 Non-PEO NEOs $ 2,474,388 $ (1,350,182) $ 2,029,238 $ 1,321,927 $ 186,151 2020 PEO $ 7,370,894 $ (4,500,157) $ 6,904,798 $ 5,224,388 $ (558,588) Non-PEO NEOs $ 1,640,642 $ (781,373) $ 1,198,887 $ 331,885 $ (68,381) | | | |
| Non-PEO NEO Average Total Compensation Amount | $ 1,675,659 | 1,836,308 | 2,474,388 | 1,640,642 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ (222,491) | (42,128) | 4,661,522 | 2,321,660 |
| Adjustment to Non-PEO NEO Compensation Footnote | Equity award adjustments Year Executive(s) SCT Total Deduct grant date fair value of equity awards reported in SCT Add year-end value of unvested equity awards granted in year Change in value of unvested equity awards granted in prior years Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year Change in value of equity awards granted in prior years which vested in year 2023 PEO $ 7,059,325 $ (5,200,178) $ 1,613,810 $ (5,825,994) $ 536,479 Non-PEO NEOs $ 1,675,659 $ (971,147) $ 212,290 $ (332,625) $ (891,449) $ 84,781 2022 PEO $ 8,523,732 $ (5,100,321) $ 2,608,474 $ (11,166,139) $ 599,000 Non-PEO NEOs $ 1,836,308 $ (1,025,211) $ 537,397 $ (1,446,374) $ 55,752 2021 PEO $ 9,199,748 $ (4,700,022) $ 6,694,551 $ 14,514,792 $ 3,135,059 Non-PEO NEOs $ 2,474,388 $ (1,350,182) $ 2,029,238 $ 1,321,927 $ 186,151 2020 PEO $ 7,370,894 $ (4,500,157) $ 6,904,798 $ 5,224,388 $ (558,588) Non-PEO NEOs $ 1,640,642 $ (781,373) $ 1,198,887 $ 331,885 $ (68,381) | | | |
| Compensation Actually Paid vs. Total Shareholder Return | Description of Relationship Between PEO and Other NEO Compensation Actually Paid, Company TSR, and Peer Group TSR The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, the Company’s cumulative TSR over the four most recently completed fiscal years, and the TSR of the S&P 500 Health Care Index over the same period. | | | |
| Compensation Actually Paid vs. Net Income | Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Income The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Net Income during the four most recently completed fiscal years. | | | |
| Compensation Actually Paid vs. Company Selected Measure | Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Adjusted EBITDA Margin The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our adjusted EBITDA margin during the four most recently completed fiscal years. | | | |
| Total Shareholder Return Vs Peer Group | Description of Relationship Between PEO and Other NEO Compensation Actually Paid, Company TSR, and Peer Group TSR The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, the Company’s cumulative TSR over the four most recently completed fiscal years, and the TSR of the S&P 500 Health Care Index over the same period. | | | |
| Tabular List, Table | • Core Sales Growth • Free Cash Flow • Adjusted EBITDA Margin | | | |
| Total Shareholder Return Amount | $ 81.17 | 113.60 | 152.02 | 113.80 |
| Peer Group Total Shareholder Return Amount | 143.18 | 140.29 | 143.09 | 113.45 |
| Net Income (Loss) | $ (100,200,000) | $ 243,100,000 | $ 340,500,000 | $ 33,300,000 |
| Company Selected Measure Amount | 0.181 | 0.201 | 0.197 | 0.130 |
| PEO Name | Amir Aghdaei | | | |
| Additional 402(v) Disclosure | The amounts shown in the Compensation Actually Paid columns have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table (“SCT”) Total with certain adjustments as described below. | | | |
| Measure:: 1 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Core Sales Growth | | | |
| Measure:: 2 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Free Cash Flow | | | |
| Measure:: 3 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Adjusted EBITDA Margin | | | |
| Non-GAAP Measure Description | We determined adjusted EBITDA margin, calculated consistent with how the Company reports adjusted EBITDA to the public, divided by the Company’s total net sales, to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2023. This performance measure may not have been the most important financial performance measure for years 2021 and 2020, and we may determine a different financial performance measure to be the most important financial performance measure in future years. | | | |
| PEO | Equity Awards Granted During the Year, Vested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ (5,200,178) | $ (5,100,321) | $ (4,700,022) | $ (4,500,157) |
| PEO | Equity Awards Granted During the Year, Unvested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 1,613,810 | 2,608,474 | 6,694,551 | 6,904,798 |
| PEO | Equity Awards Granted In Prior Years, Unvested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (5,825,994) | (11,166,139) | 14,514,792 | 5,224,388 |
| PEO | Equity Awards Granted In Prior Years, Vested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 536,479 | 599,000 | 3,135,059 | (558,588) |
| Non-PEO NEO | Equity Awards Granted During the Year, Vested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (971,147) | (1,025,211) | (1,350,182) | (781,373) |
| Non-PEO NEO | Equity Awards Granted During the Year, Unvested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 212,290 | 537,397 | 2,029,238 | 1,198,887 |
| Non-PEO NEO | Equity Awards Granted In Prior Years, Unvested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (332,625) | (1,446,374) | 1,321,927 | 331,885 |
| Non-PEO NEO | Equity Awards Granted In Prior Years, Vested [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 84,781 | $ 55,752 | $ 186,151 | $ (68,381) |
| Non-PEO NEO | Equity Awards that Failed to Meet Vesting Conditions [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ (891,449) | | | |
